Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin Aet al.
New England Journal of Medicine · 2024; 391(13):1193-1205
This study evaluates Tirzepatide (maximum tolerated dose of 10 mg or 15 mg) given as a once-weekly injection for 52 weeks, compared with placebo in relation to Change in apnea-hypopnea index (AHI, number of breathing pauses per hour of sleep) from baseline to week 52.
Evidence-Based Research: Glp1 Sleep Apnea Rct
Key facts at a glance
- DOI
- 10.1056/nejmoa2404881
- PMID
- 38912654
- PMC
- PMC11598664
- Journal
- New England Journal of Medicine
- Year
- 2024
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- Study type
- rct
- Evidence level
- Ib
- Sample size
- 469
- Intervention
- Tirzepatide (maximum tolerated dose of 10 mg or 15 mg) given as a once-weekly injection for 52 weeks, compared with placebo
- Primary outcome
- Change in apnea-hypopnea index (AHI, number of breathing pauses per hour of sleep) from baseline to week 52
- Follow-up
- 52 weeks
- Funding
- industry
- Effect size
- AHI reduction difference vs placebo: -20.0 events/h (Trial 1) and -23.8 events/h (Trial 2); mean body weight loss 17-20%
- Registration
- NCT05412004
- Open access
- true
Study Overview
This study examined the effects of Tirzepatide (maximum tolerated dose of 10 mg or 15 mg) given as a once-weekly injection for 52 weeks, compared with placebo on Change in apnea-hypopnea index (AHI, number of breathing pauses per hour of sleep) from baseline to week 52.
Key Findings
The results suggest the intervention has potential clinical benefits.
Clinical Conclusions
See original publication.
Abstract
"This randomized controlled trial enrolled 469 participants, investigating the effects of Tirzepatide (maximum tolerated dose of 10 mg or 15 mg) given as a once-weekly injection for 52 weeks, compared with placebo on Change in apnea-hypopnea index (AHI, number of breathing pauses per hour of sleep) from baseline to week 52.
Funding & conflicts of interest
Funding: industry
COI: Study sponsored by Eli Lilly; many authors reported consulting fees, research support, or employment ties to Eli Lilly and other pharmaceutical companies
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy